Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Study showing prevalence of cow-to-cow TB transmission emphasises need for more accurate diagnostic

New research about the transmission of bovine TB, published in the journal eLife this week, shows that the chance of cross infection between cows is much greater than between badgers and cows, with TB passing between members of the same species at least twice as often as transmission between cow and badger, or badger to cow.
  • December 18, 2019
  • Research
  • badgers, technology
cow

Scientists from the University of Edinburgh, in collaboration with the APHA (Animal and Plant Health Agency) amongst others, analysed the entire genetic make-up of the mycobacteria that causes TB (Mycobacterium bovis) from 230 badgers and 189 cattle over a 15 year period in a process known as whole genome sequencing.

The official test to confirm a herd has an Officially TB free status is called the Tuberculin skin test (SICCT). Its sensitivity – the ability of the test to correctly identify those animals with the disease – varies between 50 and 90% depending on the conditions under which it is carried out. This means that infected animals are being missed; leaving them in the herd to infect others.

Responding to the research, PBD Biotech’s Chief Scientific Officer Dr Cath Rees said:

“This paper provides interesting new insights into the reservoir of M. bovis infection that exists in cattle and badger populations. The findings show the ease with which cattle can transmit TB to other cattle, at least twice as often than infection between badger and cow. The study demonstrates why it is vital that an accurate diagnostic is used to root out TB from a herd – ensuring no infected animals remain.

“The known limitations of the existing tests cast doubt on what ‘TB-free status’ now genuinely means. This is exactly why we have developed Actiphage – to directly detect and identify live mycobacteria, providing another way to detect infection when tests based on an immune response fail.”

Actiphage® is a rapid test for the presence of viable mycobacteria in blood or milk samples. It can provide accurate results within hours and can detect very low levels of mycobacteria, before the animal starts shedding bacteria into the environment. It therefore enables improved disease management.

Authors of the ‘Combining genomics and epidemiology to analyse bi-directional transmission of Mycobacterium bovis in a multi-host System’ paper say the findings of the study, funded by the Biotechnology and Biological Sciences Research Council, Defra and the Wellcome Trust, could improve control strategies, reduce disease transmission and cut associated costs.

Share:

Related posts

Loading...
Tomas Richardson

Disruptive phage technology attracts top scientist to PBD Biotech

January 18, 2022
“PBD Biotech has developed an exciting and potentially disruptive technology that uses bacteriophage to improve the molecular diagnosis of tuberculosis” says Dr Tomas Richardson.
Tomas Richardson

Disruptive phage technology attracts top scientist to PBD Biotech

January 18, 2022
“PBD Biotech has developed an exciting and potentially disruptive technology that uses bacteriophage to improve the molecular diagnosis of tuberculosis”...
huynh-phg21-poster-final-web

Multiplicity of infection – Albert Huynh presents research at Phages 2021

September 22, 2021
Albert’s research, ‘Use of 2, 3, 5-Triphenyltetrazolium chloride (TTC) to assay the kinetics of phage and host interactions’, is sponsored by PBD Biotech through the BBSRC CASE initiative, and was co-authored by fellow Nottingham student Philip J. Hill and PBD...
huynh-phg21-poster-final-web

Multiplicity of infection – Albert Huynh presents research at Phages 2021

September 22, 2021
Albert’s research, ‘Use of 2, 3, 5-Triphenyltetrazolium chloride (TTC) to assay the kinetics of phage and host interactions’, is sponsored...
PBD Biotech - blood tests

Exploiting phage to detect Mycobacteria – things you discover when you don’t know not to look

July 26, 2016
Reported by Dr Catherine Rees at Viruses of Microbes 2016 Conference.
PBD Biotech - blood tests

Exploiting phage to detect Mycobacteria – things you discover when you don’t know not to look

July 26, 2016
Reported by Dr Catherine Rees at Viruses of Microbes 2016 Conference.

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More